Evidence map›Paper›PMID 42366401›Full record

ReviewAlzheimer's research & therapy2026

Facial phenotypes in Alzheimer's disease: from neurobiology to artificial intelligence.

Wenshan Sun, Rong Xing, Jian Zhou, Yong Li, Gelin Xu

Abstract readReview
In one paragraph

Review in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wenshan Sun *Department of Neurology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Rong Xing *School of Economics and Management, Nanjing University of Science and Technology, Nanjing, China.
Jian ZhouSchool of Economics and Management, Nanjing University of Science and Technology, Nanjing, China.
Yong LiSchool of Computer Science and Engineering and Key Laboratory of New Generation Artificial Intelligence Technology and Its Interdisciplinary Applications, Southeast University, Nanjing, China. mysee1989@gmail.com.
Gelin XuDepartment of Neurology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, China. gelinxu@nju.edu.cn.

Funding

Major Project of Philosophy and Social Science Research for Universities of Jiangsu Province KYCX25_0823 to RXNational Natural Science Foundation of China 82171330Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0504800, 2023ZD0504801, 2023ZD0504802, 2023ZD0504803, 2023ZD0504804Shenzhen Talent Introduction Fund 4004013
6 · The paper itself

Abstract

Facial analysis is increasingly being explored as a source of scalable behavioral signals relevant to Alzheimer's disease (AD) and AD-related cognitive impairment. In this narrative review, informed by a structured literature search, we summarize current evidence on the biological and behavioral basis of facial alterations in AD, with particular emphasis on affective expressivity, neuropsychiatric manifestations, and dynamic facial behavior. We also review representative artificial intelligence-based facial analysis methods, including commonly used datasets, feature representations, and modeling strategies, ranging from facial landmarks and texture descriptors to spatiotemporal video models, multimodal fusion, and language-enhanced frameworks. Current evidence remains limited by small and largely single-center cohorts, heterogeneity in acquisition settings and outcome definitions, inadequate control of confounding factors, limited external validation, poor calibration reporting, and persistent concerns regarding interpretability and clinical specificity. Within the evolving biomarker-based diagnostic framework of AD, facial analysis is better viewed as a candidate, non-specific, and context-dependent tool for auxiliary risk stratification, triage support, and longitudinal monitoring rather than as stand-alone diagnostic tests. Future progress will depend on standardized data acquisition, integration with clinical and biomarker data, improved explainability, and prospective real-world validation.

Indexed as

Alzheimer DiseaseArtificial IntelligenceFacial ExpressionNeurobiologyHumansPhenotypeAffective computingAlzheimer’s diseaseArtificial intelligenceFacial phenotypeNeuropsychiatric symptoms

Identifiers

PMID42366401
PMCPMC13591852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.